文献速递急性肾损伤慢性肾脏病遗传性与小管间质肾病

质子泵抑制剂使用与不良肾脏结局风险之间的关联:系统综述与荟萃分析

The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

结果显示PPI使用者急性肾损伤(RR 1.44)、慢性肾脏病(RR 1.36)、急性间质性肾炎(RR 3.61)和终末期肾病(RR 1.42)风险均显著升高,但证据质量低或不足。

要点

  • PPI使用者急性肾损伤风险显著升高(RR 1.44,95%CI 1.08-1.91),证据质量低。
  • PPI使用者慢性肾脏病风险显著升高(RR 1.36,95%CI 1.07-1.72),证据质量低。
  • PPI使用者急性间质性肾炎(RR 3.61)和终末期肾病(RR 1.42)风险升高,证据质量不足。

核心结论

  • PPI使用与不良肾脏结局相关,但这些发现基于观察性研究和低质量证据,需要更多严谨研究进一步阐明。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、SCOPUS、Web of Science、CINAHL、Cochrane Library及灰色文献,无语言限制,截至2016年10月31日。
  • 采用随机效应模型合并风险比(RR)和置信区间(CI),并使用GRADE系统评估各结局的证据强度(SOE)。

主要发现

  • 与未使用PPI者相比,PPI使用者急性肾损伤风险显著升高(RR 1.44,95%CI 1.08-1.91;P=0.013;SOE低)。
  • 与未使用PPI者相比,PPI使用者慢性肾脏病风险显著升高(RR 1.36,95%CI 1.07-1.72;P=0.012;SOE低)。
  • 与未使用PPI者相比,PPI使用者急性间质性肾炎风险升高(RR 3.61,95%CI 2.37-5.51;P<0.001;SOE不足)。
  • 与未使用PPI者相比,PPI使用者终末期肾病风险升高(RR 1.42,95%CI 1.28-1.58;P<0.001;SOE不足)。

关键数值与推荐

  • 不良肾脏结局包括急性间质性肾炎、急性肾损伤、慢性肾脏病和终末期肾病。
  • 证据强度采用GRADE系统评估:急性肾损伤和慢性肾脏病为低质量证据,急性间质性肾炎和终末期肾病为证据不足。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 这些发现基于观察性研究。
  • 证据质量低。
  • 需要更多严谨研究进一步阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Existing epidemiological studies illustrate that proton pump inhibitors (PPIs) may be related to adverse kidney outcomes. To date, no comprehensive meta-analysis has been conducted to evaluate and quantify this association. METHODS: We performed a systematic review and meta-analysis of studies to assess the association between PPI use and the risk of adverse kidney outcomes. We searched MEDLINE, Embase, SCOPUS, Web of Science, CINAHL, Cochrane Library and grey literature with no language restrictions (through 31 October 2016). Adverse kidney outcomes were acute interstitial nephritis (AIN), acute kidney injury (AKI), chronic kidney disease (CKD) and end-stage renal disease (ESRD). The risk ratios (RRs) and confidence intervals (CIs) were pooled using a random effects model. The strength of evidence (SOE) for each outcome was assessed using the Grading of Recommended Assessment, Development and Evaluation system. RESULTS: Of 2037 identified studies, four cohort and five case-control studies with ∼2.6 million patients were included. Of these, 534 003 (20.2%) were PPI users. Compared with non-PPI users, PPI users experienced a significantly higher risk of AKI [RR 1.44 (95% CI 1.08-1.91); P = 0.013; SOE, low] and CKD [RR 1.36 (95% CI 1.07-1.72); P = 0.012; SOE, low]. Moreover, PPIs increased the risk of AIN [RR 3.61 (95% CI 2.37-5.51); P < 0.001; SOE, insufficient] and ESRD [RR 1.42 (95% CI 1.28-1.58); P < 0.001; SOE, insufficient]. CONCLUSION: PPI usage was associated with adverse kidney outcomes; however, these findings were based on observational studies and low-quality evidence. Additional rigorous studies are needed for further clarification.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018. PMID: 28339835. doi:10.1093/ndt/gfw470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。